BillionToOne Inc

BLLN

Market cap $3.22B

BillionToOne, Inc. (BLLN) Q4 2025 Earnings Call Transcript

BillionToOne delivers strong growth in molecular diagnostics, achieving profitability and raising 2026 revenue guidance to $430–$445 million. BillionToOne's Q4 sales rose 113% to $96.1 million, driven by prenatal testing; oncology growth was slower sequentially but remains a long-term diversification lever. I view current guidance as conservative, with recent product launches and coverage deals not fully reflected in the outlook, supporting further upside potential.

Although the revenue and EPS for BillionToOne (BLLN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the fourth quarter and full year ended December 31, 2025 and raised guidance for full year 2026.

MENLO PARK, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for fourth quarter and full year ended December 31, 2025 after the market close on Wednesday, March 4, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.

Singapore-based Napean Trading & Investment bought 233,333 shares of BillionToOne in the fourth quarter. The quarter-end position value increased by $19,095,973, reflecting the new acquisition of shares.

Northstar PGx™ and Northstar Select CH™ extend clinical insight and utility of Northstar Select® all from the same blood-draw MENLO PARK, Calif., Feb. 10, 2026 /PRNewswire/ --  BillionToOne , Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the launch of Northstar PGx and Northstar Select CH.

BillionToOne Expands Its Leadership in Hemolytic Disease of the Fetus and Newborn (HDFN) and Extends Fetal Antigen Testing to Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) MENLO PARK, Calif., Feb. 9, 2026 /PRNewswire/ -- BillionToOne , Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the launch of UNITY's expanded Red Blood Cell (RBC) Fetal Antigen NIPT and a first-and-only Platelet Fetal Antigen NIPT.

Integration enables seamless ordering and results delivery within Epic for UNITY Complete® and Northstar® tests, creating a better patient and provider experience MENLO PARK, Calif., Jan. 15, 2026 /PRNewswire/ -- BillionToOne , Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced a collaboration with Epic , the nation's most widely used comprehensive electronic health record (EHR).

MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reiterated the full year 2025 guidance of $293 million to $299 million with positive GAAP operating income and initiated the full year 2026 guidance.